Emerging precision neoadjuvant systemic therapy for patients with resectable non-small cell lung cancer: current status and perspectives

Emerging precision neoadjuvant systemic therapy for patients with resectable non-small cell lung cancer: current status and perspectives

Abstract Over the past decade, targeted therapy for oncogene-driven NSCLC and immune checkpoint inhibitors for non-oncogene-driven NSCLC, respectively, have greatly improved the survival and quality of life for patients with unresectable NSCLC. Increasingly, these biomarker-guided systemic therapies...

Πλήρης περιγραφή

Λεπτομέρειες βιβλιογραφικής εγγραφής
Κύριοι συγγραφείς: Luis A. Godoy, Joy Chen, Weijie Ma, Jag Lally, Kyra A. Toomey, Prabhu Rajappa, Roya Sheridan, Shirish Mahajan, Nicholas Stollenwerk, Chinh T. Phan, Danny Cheng, Robert J. Knebel, Tianhong Li
Μορφή: Άρθρο
Γλώσσα:English
Έκδοση: BMC 2023-01-01
Σειρά:Biomarker Research
Θέματα:
NSCLC
Resectable
Neoadjuvant
Immune checkpoint inhibitor (ICI)
Targeted therapy
Precision oncology
Διαθέσιμο Online:https://doi.org/10.1186/s40364-022-00444-7

Διαδίκτυο

https://doi.org/10.1186/s40364-022-00444-7

Παρόμοια τεκμήρια